Maryland State Retirement & Pension System Has $2.19 Million Position in Edwards Lifesciences Corporation $EW

Maryland State Retirement & Pension System grew its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 2.1% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 27,974 shares of the medical research company’s stock after buying an additional 579 shares during the period. Maryland State Retirement & Pension System’s holdings in Edwards Lifesciences were worth $2,188,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Quantbot Technologies LP bought a new stake in Edwards Lifesciences in the first quarter valued at about $26,000. SouthState Corp bought a new stake in Edwards Lifesciences in the first quarter valued at about $27,000. Global X Japan Co. Ltd. increased its stake in Edwards Lifesciences by 116.1% in the first quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 216 shares during the period. Tradewinds Capital Management LLC increased its stake in Edwards Lifesciences by 102.5% in the first quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 205 shares during the period. Finally, Rossby Financial LCC bought a new stake in Edwards Lifesciences in the first quarter valued at about $29,000. Institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the firm’s stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at approximately $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the transaction, the insider directly owned 206,900 shares in the company, valued at approximately $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.29% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on EW shares. Deutsche Bank Aktiengesellschaft upped their target price on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the company a “buy” rating in a research note on Friday, July 25th. Piper Sandler upped their price objective on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the stock an “overweight” rating in a research note on Friday, July 25th. Stifel Nicolaus set a $85.00 price objective on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research note on Monday, September 22nd. Canaccord Genuity Group upped their price objective on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the stock a “hold” rating in a research note on Friday, July 25th. Finally, Evercore ISI set a $88.00 price objective on shares of Edwards Lifesciences and gave the stock an “outperform” rating in a research note on Tuesday. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $87.06.

Edwards Lifesciences Price Performance

EW opened at $74.02 on Friday. Edwards Lifesciences Corporation has a one year low of $64.89 and a one year high of $83.00. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The company’s 50 day simple moving average is $78.09 and its 200-day simple moving average is $76.10. The stock has a market capitalization of $43.46 billion, a P/E ratio of 10.65, a price-to-earnings-growth ratio of 3.61 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The business had revenue of $1.53 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same period in the prior year, the firm earned $0.70 earnings per share. Edwards Lifesciences’s revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.